LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
61 hedge funds and large institutions have $128M invested in LogicBio Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 9 closing their positions.
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
3% more funds holding
Funds holding: 59 → 61 (+2)
3% less capital invested
Capital invested by funds: $133M → $128M (-$4.41M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$913K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$811K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$685K |
| 4 |
BlackRock
New York
|
+$661K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$199K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$710K |
| 2 |
Millennium Management
New York
|
-$451K |
| 3 |
JP Morgan Chase
New York
|
-$366K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$248K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$154K |
LOGC Hedge Fund Activity: Q1 2021 in Review
61 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q1 2021, worth a combined $128M — down 3.3% from $133M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new LOGC positions and 9 closed out — a net gain of 3 holders — while 17 added to existing stakes and 14 trimmed.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $913K. The largest seller was EcoR1 Capital, cutting an estimated $710K.
- 61 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q1 2021, up from 59 in Q4 2020.
- Funds reported $128M of LogicBio Therapeutics, Inc. Common Stock stock for Q1 2021, down 3.3% quarter-over-quarter.
- 12 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q1 2021 and 9 closed out, a net change of +3 holders.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q1 2021 was GSA Capital Partners, an estimated $913K added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q1 2021 was EcoR1 Capital, an estimated $710K sold.
Based on aggregated 13F filings for Q1 2021.